As of 2026-06-26 · Last updated: 2026-07-07 · Source: SEC EDGAR (10-K), stockanalysis (5-year financials), TradingView (price, financials, consensus), Company IR · Prices & financials updated periodically (not real-time) · Information tool (not investment advice)
Debt burden is moderate, so it can be affected by the economic cycle.
Metrics · D/E ~139% · Current Ratio 1.50
💲Is the price expensive now?
On the expensive side
Even accounting for growth expectations, the price is set high.
Metrics · P/E 43.5 · P/B 43.0
💡Hyper-growth GLP-1 pharma (Zepbound, Mounjaro): TTM revenue +47%, 47% operating margin, 108% ROE. Debt is moderate, but ~43x P/E and P/B price in growth.
Compiled from public financial data. Not a recommendation to buy or sell any security. · Source: TradingView (margins, debt, liquidity, P/B are TTM), as of 2026-06-26
Business Summary · Key Value Metrics
A global pharma company in diabetes and obesity (Mounjaro, Zepbound) plus oncology, immunology, and neuroscience. Explosive GLP-1 growth pushed TTM (2026) revenue to $72.2B. FY2025 revenue $65.2B with a 40.3% operating margin (note: TTM operating margin 47.3%).
Eli Lilly is growing explosively in GLP-1 obesity and diabetes therapies (tirzepatide: Mounjaro, Zepbound), forming a duopoly with Novo Nordisk. Its moat rests on dual-receptor technology, a deep late-stage pipeline (donanemab for Alzheimer's, oral GLP-1 orforglipron), and large-scale manufacturing investment. TTM operating margin is 47.3% (source: company IR, TradingView).
GLP-1 Market Lead
Mounjaro and Zepbound are surging in obesity and diabetes, forming a duopoly with Novo Nordisk.
Pipeline Depth
A deep late-stage pipeline, including donanemab (Alzheimer's) and oral orforglipron (obesity).
Manufacturing Moat
A $9B+ GLP-1 capacity buildout; production capacity itself is a barrier to entry.
Brand and R&D
140 years in pharma, with a physician-patient network and an R&D culture.
10-Year Financial Trends
Revenue's 9-year CAGR is +13.3%, but GLP-1 has accelerated it lately—+32% in 2024 and +45% in 2025, reaching $65.2B. Diluted EPS swung from -$0.19 in 2017 (a one-time tax charge) to $11.71 in 2024 and $22.95 in 2025 (+96%), a 9-year CAGR of +27.5%. Operating margin widened to about 40% in 2025 (source: SEC EDGAR 10-K, stockanalysis, company IR).
9-Year CAGR: Revenue +13.3% · Operating Income Surged (+43%, last 4 yrs) · Net Income +25.3% · EPS +27.5%
Source: SEC EDGAR 10-K, stockanalysis, company IR. Fiscal year (December) GAAP basis; EPS is diluted. Revenue and EPS cover 10 years (SEC); operating income, operating margin, ROE, and P/E cover the last 5 years (stockanalysis) due to data limits.
Mega-Cap Value Metric Comparison
It forms a duopoly with Novo Nordisk (NVO) in the GLP-1 obesity and diabetes market. Eli Lilly's edge is its dual-receptor agonist and deep pipeline, and with a 47.3% TTM operating margin and 107.6% ROE it ranks among pharma's best. Its P/E of 43x is high, though (source: TradingView, industry data).
Metric
★ LLY
NVO
MRK
Operating Margin
47.3%
~45%
~28%
P/E (TTM)
43.5
~20
~13
Revenue YoY Growth
+47.4%
High
Moderate
P/E and operating margin = TTM · Source: TradingView, company filings, 2026-06-26. GLP-1 is an LLY-NVO duopoly.
Key Risk Factors (from 10-K)
●
High Valuation— At ~43x P/E and P/B, much of continued GLP-1 growth is priced in; any shortfall could sink the stock.Source: TradingView
Q. What are Eli Lilly's (LLY) key value-investing metrics?P/E (TTM) 43.5, ROE 107.6%, operating margin 47.3%, net margin 35.0%, TTM revenue +47.4%, and a 9-year EPS CAGR of +27.5% (source: TradingView, company IR, as of 2026-06-26).
Q. What is GLP-1 and why does it matter?GLP-1 is a class of obesity and diabetes drugs, and Lilly's Mounjaro and Zepbound are its key growth engines. With the global obesity market projected above $100B, it is the source of the revenue and profit surge.
Q. Isn't the stock expensive?At ~43x P/E, much of the growth expectation is priced in. Some see a PEG of about 1.0–1.1 as reasonable versus growth, but a slowdown risks a re-rating. We don't offer valuation calls.